2024 AMGA Annual Report
The AMGA mission drives a robust set of core competencies—education, standard setting, and advocacy—that serve to advance the AMGA community and the guiding industry. The mission positions the organization to tackle big industry challenges while also serving individual guides with career development and community.
In 2024, the AMGA executed high-impact initiatives that touched on all three areas of the mission. On the advocacy front, the passage of the EXPLORE Act in December 2024 was a landmark achievement for guides that will give rise to a new era of increased access and streamlined permitting. In the realm of education, the AMGA redesigned the entrance to the Alpine Guide Program to provide terrain-specific training in snow and glacier guiding, and alpine rock guiding. The new programs will enable guides to quickly gain qualification to work in the classic alpine ranges and will better meet the needs of AMGA Accredited Businesses. As a standard-setting organization, the AMGA made important refinements to the AMGA Scope of Practice including the introduction of a terrain complexity scale.
Read More
Small molecule GLP-1s in Science Magazine (featuring Ambrosia!)
Drugs that mimic glucagonlike peptide-1 (GLP-1), such as semaglutide—marketed as Ozempic or Wegovy—have revolutionized the treatment of obesity and type 2 diabetes, but they have major drawbacks. “[They] are expensive to manufacture, they have to be refrigerated, and they often have to be injected because they cannot go through the gastrointestinal tract without being degraded,” explains Alejandra Tomas, a cell biologist at Imperial College London who studies the cellular receptor GLP-1 drugs target. That’s all because they consist of peptides, or long chains of amino acids.
Read More
Opanga Secures Strategic Funding from Boulder Ventures, Cisco Investments, Grayhawk Capital and Trilogy Equity Partners
SEATTLE – April 15, 2025 – Opanga, a global leader in AI-powered network optimization solutions, today announced it has received strategic investments from Boulder Ventures, Cisco Investments, the global corporate venture investment arm of Cisco, Grayhawk Capital and Trilogy Equity Partners.
This financing will support future product development, sales and marketing for Opanga’s AI-driven platform, RAIN, as the company continues expanding its deployments with global telecom operators to enhance network optimization and improve real-time customer experience across the telecom industry.
Read More
Tariff Chaos is a C-Suite Problem
With the US imposing harsh protectionist measures via aggressive import taxes, American and global manufacturers are racing to find solutions and responses. Margins are under siege. Strategic sourcing is being rewritten in real time.
Here’s the hard truth: if you’re waiting for your supply chain team or ERP vendor to sort this out, you’re already behind.
This is not just a compliance problem. It’s a C-Suite problem. And it demands a C-Suite solution.
Read More
Black Bear Energy's 10th Anniversary!
Today Black Bear Energy Inc. turns ten! We are humbled to represent over 100 of the most forward-thinking real estate owners, honored to work with many leading partners and privileged to be a part of this industry.
My biggest learning over this past decade; the importance of culture to the success of an organization. Thank you to everyone who has helped shape this company and continues to do so.
We love what we do and we are just getting started. ONWARD!!
Read More
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). Both trials successfully achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints and demonstrated a favorable safety and tolerability profile.
Read More
Antithesis Marks One-Year Anniversary With Customer Growth, New Funding, Company Expansion
VIENNA, Va., Feb. 13, 2025 /PRNewswire/ --Antithesis, the autonomous software testing company, today marks its first year anniversary since launching out of stealth with the announcement of new funding and the expansion of its customer base, employee count, and board.
Read More
Executive Spotlight: 10 Questions for Drew Torbin
What does it take to lead a company that’s reshaping the future of energy? Drew Torbin, President of Black Bear Energy, a Legence Company, combines a passion for clean technology with a deep commitment to culture and community. In this executive spotlight interview, Drew dives into the exciting trends driving renewable energy, the unique dynamics of living and working in Boulder, and how Black Bear’s people-first culture keeps the team thriving.
Read More
Nederland senior named a Regeneron Science Talent Search scholar
Keahi Pelkum Donahue, a senior at Nederland Middle Senior High School, recently was named one of the top 300 scholars in the Regeneron Science Talent Search.
Donahue entered his project, “Forecasting Solar Flares with Transformer Networks,” in the science and math competition for high school seniors. The 300 scholars were selected from nearly 2,500 entrants. Each scholar will be awarded $2,000 each, as well as $2,000 for their schools.
Read More
